Combining Independent Drug Classes into Superior, Synergistically Acting Hybrid Molecules (pages 8743–8746)
Dr. Andreas Müller-Schiffmann, Dr. Julia März-Berberich, Dr. Aksana Andreyeva, Dr. Raik Rönicke, Dr. Dirk Bartnik, Dr. Oleksandr Brener, Dr. Janine Kutzsche, Dr. Anselm H. C. Horn, Dipl.-Chem. Marco Hellmert, Dr. Jolanta Polkowska, Prof. Dr. Kurt Gottmann, Prof. Dr. Klaus G. Reymann, Dr. S. Aileen Funke, Dr. Luitgart Nagel-Steger, Dr. Christine Moriscot, Prof. Dr. Guy Schoehn, Prof. Dr. Heinrich Sticht, Prof. Dr. Dieter Willbold, Prof. Dr. Thomas Schrader and Prof. Dr. Carsten Korth
Article first published online: 4 OCT 2010 | DOI: 10.1002/anie.201004437
More than the sum of its parts: Novel hybrid compounds consisting of an organic β-sheet-breaking moiety and a signaling, D-enantiomeric Aβ-recognizing peptide moiety have been designed (see picture). The compounds, which were chemically synthesized and characterized by several techniques, combine rational design and drug selection from libraries and inhibit Aβ oligomerization and Aβ-induced synaptic pathology.